ABSTRACT
The outbreak of COVID-19 has been revealed some pathogenic mechanisms which are indicating the role of virus in the pathogenesis of diseases such as diabetes mellitus, autoimmune and cardiovascular diseases. COVID-19 results in deterioration of glycemic control in diabetic patients and even in some cases developed new onset diabetes mellitus which are indicating the possible interfering role of SARS-CoV-2 in different metabolic pathways. Furthermore, during COVID-19 exacerbation of inactivated or de novo autoimmune diseases have been reported which indicate the causative role of virus in the stimulation of immune system and aggravation of autoimmune diseases through different mechanisms. In this report, a 31 year old male case of systemic lupus erythematosus (SLE) has been introduced who developed flu like illness, generalized edema and renal failure following the administration of third dose of Sinopharm BIBP COVID-19 (Sinopharm Beijing institute of Biological Products, China). During hospital course, proper therapeutic response was not achieved despite biopsy proven class IV lupus nephritis and standard therapy with methyl prednisolone and cyclophosphamide. He discharged with administration of routine hemodialysis thrice weekly. According to the course of disease, findings of biopsy and serologic tests, there were some challenging scenarios that are discussed in this report. © 2022, Bushehr University of Medical Sciences. All rights reserved.